Below are four digital health rule changes that will bring opportunity to pharma, according to a PwC Health Research Institute analysis.
1. Digital health precertification: Pharma companies with high marks on regulatory quality are now eligible for shorter reviews and ONC approval.
2. Companion applications: Digital health apps that are intended to supplement prescription drugs will now be regulated as labeling, meaning they will not require FDA approval.
3. Multiple-function devices: The FDA will treat each function of a digital health device as a separate entity, making it easier to have full-function products.
4. Over the counter drug digital labeling: These drugs can be approved if evidence shows the consumer can use digital labeling to select a drug for treatment.
More articles on health IT:
5 notes about CMS’ interoperability program in 2019
New HHS rules will give 125 million patients easier access to EHRs, Senate health chair says
UPS testing drones to deliver medical supplies to hospitals
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.